Despite IPO plans, Syndax raises another $5 million for epigenetic breast cancer treatment
A company in the burgeoning field of epigenetics has raised about $5 million in debt financing, right on the heels of refiling for an initial public offering. Syndax Pharmaceuticals, a late-stage Massachusetts biotech, postponed an IPO from June but, according to an August 28 filing, still plans to raise $60 million when it goes public. It’s offering […]